XORTX THERAPEUTICS INC (XRTX.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:XRTX - CA98420Q3061 - Common Stock
XRTX.CA Key Statistics, Chart & Performance
The current stock price of XRTX.CA is 0.81 CAD. In the past month the price decreased by -20.59%. In the past year, price decreased by -50.31%.
XRTX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.88 | 3.65B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.61B | ||
| CRON.CA | CRONOS GROUP INC | 25.07 | 1.44B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.11 | 881.76M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 655.86M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 5.27 | 653.05M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 592.76M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 528.16M | ||
| TSND.CA | TERRASCEND CORP | N/A | 405.08M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 16.78 | 383.09M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 352.50M | ||
| HITI.CA | HIGH TIDE INC | N/A | 339.40M |
Related stock screener links
About XRTX.CA
Company Profile
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Company Info
XORTX THERAPEUTICS INC
3710 - 33rd Street NW
Calgary ALBERTA CA
Employees: 3
Phone: 14034557727
XORTX THERAPEUTICS INC / XRTX.CA FAQ
What does XORTX THERAPEUTICS INC do?
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
What is the current price of XRTX stock?
The current stock price of XRTX.CA is 0.81 CAD.
Does XRTX stock pay dividends?
XRTX.CA does not pay a dividend.
What is the ChartMill rating of XORTX THERAPEUTICS INC stock?
XRTX.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of XORTX THERAPEUTICS INC (XRTX.CA) based on its PE ratio?
XORTX THERAPEUTICS INC (XRTX.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.65).
What is XORTX THERAPEUTICS INC worth?
XORTX THERAPEUTICS INC (XRTX.CA) has a market capitalization of 5.64M CAD. This makes XRTX.CA a Nano Cap stock.
XRTX.CA Technical Analysis
XRTX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to XRTX.CA. The financial health of XRTX.CA is average, but there are quite some concerns on its profitability.
XRTX.CA Financial Highlights
Over the last trailing twelve months XRTX.CA reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS decreased by -1213.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.13% | ||
| ROE | -98.46% | ||
| Debt/Equity | 0 |